BRPI0814363A2 - Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos - Google Patents

Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos

Info

Publication number
BRPI0814363A2
BRPI0814363A2 BRPI0814363-3A2A BRPI0814363A BRPI0814363A2 BR PI0814363 A2 BRPI0814363 A2 BR PI0814363A2 BR PI0814363 A BRPI0814363 A BR PI0814363A BR PI0814363 A2 BRPI0814363 A2 BR PI0814363A2
Authority
BR
Brazil
Prior art keywords
interferon
same
controlled release
hcv infection
release drug
Prior art date
Application number
BRPI0814363-3A2A
Other languages
English (en)
Inventor
David Gelvin Spencer
John Elliot Humphries
Leonardus Gerardus Jozef De Leede
Rudolf Verrijk
Original Assignee
Biolex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolex Therapeutics Inc filed Critical Biolex Therapeutics Inc
Publication of BRPI0814363A2 publication Critical patent/BRPI0814363A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0814363-3A2A 2007-07-25 2008-07-25 Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos BRPI0814363A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95187907P 2007-07-25 2007-07-25
US95214007P 2007-07-26 2007-07-26
US97833007P 2007-10-08 2007-10-08
US98552607P 2007-11-05 2007-11-05
PCT/US2008/071191 WO2009015336A2 (en) 2007-07-25 2008-07-25 Controlled release interferon drug products and treatment of hcv infection using same

Publications (1)

Publication Number Publication Date
BRPI0814363A2 true BRPI0814363A2 (pt) 2015-01-27

Family

ID=40282165

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814363-3A2A BRPI0814363A2 (pt) 2007-07-25 2008-07-25 Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos

Country Status (11)

Country Link
US (1) US8137661B2 (pt)
EP (1) EP2175865A4 (pt)
JP (1) JP2010534681A (pt)
KR (1) KR20100056479A (pt)
CN (1) CN101820887A (pt)
AU (1) AU2008279087A1 (pt)
BR (1) BRPI0814363A2 (pt)
CA (1) CA2694440A1 (pt)
MX (1) MX2010000965A (pt)
WO (1) WO2009015336A2 (pt)
ZA (1) ZA201000681B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI480272B (zh) * 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
RU2013127786A (ru) 2010-11-19 2014-12-27 Венус Ремедиз Лимитед Новые конъюгаты для направленной доставки лекарственного средства
ES2527510T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012003457T5 (de) 2011-10-21 2015-03-12 Abbvie Inc. Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US20140363396A1 (en) * 2012-02-01 2014-12-11 Kadmon Pharmaceuticals Llc Once daily treatment of hepatitis c with ribavirin and taribavirin
WO2013168179A2 (en) * 2012-04-03 2013-11-14 Rubicon Research Private Limited Controlled release pharmaceutical formulations of antiviral agents
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410697B1 (en) 1979-04-20 2002-06-25 Schering Corporation Process for purifying human leukocyte interferon
US6835557B1 (en) 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4749576A (en) 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
WO1997016204A1 (en) 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
AU748756B2 (en) 1997-07-18 2002-06-13 Infimed Therapeutics, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
DE69810822T2 (de) 1997-09-21 2003-11-20 Schering Corp Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infection
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
ES2172288T3 (es) 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US20030206928A1 (en) 1999-04-07 2003-11-06 Pertti Tormala Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
CN101676400A (zh) 2000-07-31 2010-03-24 比洛克西治疗公司 在浮萍中表达生物活性多肽
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
EP1443907A1 (en) 2001-11-12 2004-08-11 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
DK1587830T3 (da) 2003-01-28 2009-10-26 Academisch Ziekenhuis Leiden Peptidinhibitorer af toksiner stammende fra LL-37
US20050269364A1 (en) 2004-04-30 2005-12-08 Gibson Rayce D Inflatable seal for bin discharge system
EP1621205A1 (en) 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US20070021434A1 (en) * 2005-06-24 2007-01-25 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
CN101448497B (zh) * 2006-01-09 2013-07-10 罗马克实验室有限公司 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用

Also Published As

Publication number Publication date
AU2008279087A1 (en) 2009-01-29
CA2694440A1 (en) 2009-01-29
KR20100056479A (ko) 2010-05-27
US20090068280A1 (en) 2009-03-12
US8137661B2 (en) 2012-03-20
WO2009015336A3 (en) 2009-03-19
ZA201000681B (en) 2013-07-31
CN101820887A (zh) 2010-09-01
JP2010534681A (ja) 2010-11-11
EP2175865A2 (en) 2010-04-21
MX2010000965A (es) 2010-03-09
WO2009015336A2 (en) 2009-01-29
EP2175865A4 (en) 2012-01-11

Similar Documents

Publication Publication Date Title
BRPI0814363A2 (pt) Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
ZA201001585B (en) Spiropyrrolidines and their use against hcv and hiv infection
ATE522216T1 (de) Verwendung von 2-6-(3-amin-piperidin-1-yl)-3- methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1- ylmethyl-4-fluor-benzonitril zur behandlung von diabetes, krebs, autoimmunerkrankungen und hiv- infektionen
ZA200905762B (en) Human atobodies agaist hepatitis c virus (hcv) and uses thereof
NO20070988L (no) Vaksine for forebygging og behandling av HIV-infeksjon
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
EP2148678A4 (en) ANTIVIRAL DRUGS FOR THE TREATMENT AND PREVENTION OF DENGUE INFECTION
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
DK2155758T3 (da) Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
BRPI0822625A2 (pt) "dispositivo espaçador modular para o tratamento de infecções por próteses"
DK1983964T3 (da) Anordning til indgivelse af lægemiddel
PT1951272T (pt) Uso de lactobacillus para o tratamento de infeções virais
BRPI0715396A2 (pt) Vacinas de matriz proteíca e processos de produção e de administração de tais vacinas
IL199152A (en) Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
AP2081A (en) Oligomeric peptides and their use for the treatment of HIV infections
DK1835907T3 (da) Lægemidler til behandling eller forebyggelse af fibrotiske sygdomme
IL202450A (en) Pharmaceutical composition to treat influenza virus infection
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
EP2224943A4 (en) USE OF A HUMAN ANTIBODY TO NEUTRALIZE HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B INFECTIONS
GB2411354B (en) Use of Scutellaria for the treatment of viral infections
EP2120988A4 (en) TREATMENT OF HEPATITIS C VIRUS INFECTIONS
DK3156057T3 (da) Delmopinol-belagt dyretyggeartikel til anvendelse til forebyggelsen eller behandlingen af halitosis
EP2217573A4 (en) TREATMENT AND PREVENTION OF VIRUS INFECTIONS
IL225861A (en) Indazole-3-carboxamide derivatives and their use in the preparation of c-viral hepatitis drugs
ATE539155T1 (de) Targets und zusammensetzungen zur therapeutischen intervention bei hiv-infektion

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.